From: Investigating the citing communities around three leading health-system frameworks
Theme | Murray and Frenk (n = 111) | GHRR (n = 107) | STHSS (n = 170) |
---|---|---|---|
Meta research | |||
 Systems Thinking/Perspective/Frameworks | 4 (3.6%) | 6 (5.6%) | 49 (28.8%) |
 HPSR/HSR | 2 (1.8%) | 1 (0.9%) | 12 (7.1%) |
 Ecohealth |  |  | 4 (2.4%) |
Normative goals research | |||
 PHC | 2 (1.8%) | 6 (5.6%) | 6 (3.5%) |
 Equity/Fairness | 13 (11.7%) | 16 (15.0%) | 14 (8.2%) |
 MDGs/SDGs | 3 (2.7%) | 2 (1.9%) | 4 (2.4%) |
 Social determinants of health | 1 (0.9%) |  | 5 (2.9%) |
Health policy research | |||
 Health Systems-Strengthening/ Reform | 13 (11.7%) | 27 (25.2%) | 36 (21.2%) |
 Health Financing/Provider Payments | 13 (11.7%) | 42 (39.3%) | 15 (8.8%) |
 Global Burden of Disease | 3 (2.7%) |  |  |
 Health System Resilience/Crisis Response | 1 (0.9%) | 2 (1.9%) | 6 (3.5%) |
 Health Governance/Stewardship | 10 (9.0%) | 7 (6.5%) | 20 (11.8%) |
 Evidence-Informed Policies/Knowledge Translation | 3 (2.7%) | 3 (2.8%) | 18 (10.6%) |
 Health Policy Making Processes | 1 (0.9%) | 11 (10.3%) | 8 (4.7%) |
 Health System Assessments | 37 (33.3%) | 17 (15.9%) | 17 (10.0%) |
 Program Evaluations | 20 (18.0%) | 16 (15.0%) | 27 (15.9%) |
 Scaling up programs |  | 1 (0.9%) | 8 (4.7%) |
 Global social policy |  | 2 (1.9%) | 1 (0.6%) |
Health admin research | |||
 Health Workers/Human Resources | 7 (6.3%) | 3 (2.8%) | 14 (8.2%) |
 Supply Chain Management |  | 2 (1.9%) | 1 (0.6%) |
 Community health |  |  | 3 (1.8%) |
 Health information systems | 1 (0.9%) |  | 3 (1.8%) |
 Patient Satisfaction/System Responsiveness | 17 (15.3%) | 5 (4.7%) | 1 (0.6%) |
 Decentralization |  | 2 (1.9%) |  |
Health problems research | |||
 Tropical Diseases | 10 (9.0%) | 5 (4.7%) | 28 (16.5%) |
 Noncommunicable Diseases (NCD) | 13 (11.7%) | 3 (2.8%) | 12 (7.1%) |
 Malnutrition |  |  | 2 (1.2%) |
 Child and maternal health | 5 (4.5%) | 4 (3.7%) | 24 (14.1%) |
 Post-conflict/conflict health | 1 (0.9%) | 2 (1.9%) | 2 (1.2%) |
 Pharmacological therapies | 2 (1.8%) | 3 (2.8%) | 11 (6.5%) |
 Non-pharma therapies | 6 (5.4%) | 3 (2.8%) | 8 (4.7%) |